# Chaga Mushroom (Inonotus obliquus) Attenuates DNCB-Induced Atopic Dermatitis by Modulating Oxidative Stress and Cytokine Expression

**Authors:** Junxiao Liu, Qun Zhang, Tianze Yang, Chang Liu, S. D. N. Kaushalya, Eun-kyung Kim, Yujiao Tang

PMC · DOI: 10.4014/jmb.2510.10032 · Journal of Microbiology and Biotechnology · 2026-01-22

## TL;DR

Chaga mushroom extract may help treat atopic dermatitis by reducing inflammation and oxidative stress.

## Contribution

The study demonstrates the therapeutic potential of a Chaga mushroom by-product in managing atopic dermatitis.

## Key findings

- E-CME treatment improved dermatitis scores and reduced mast cell infiltration in mice.
- E-CME modulated serum immunoglobulin levels and oxidative stress markers.
- E-CME enhanced splenocyte viability and reduced inflammatory cytokine expression.

## Abstract

Recent studies highlight the immunomodulatory properties of Chaga mushrooms. Atopic dermatitis (AD) is a multifactorial skin disorder involving interactions between innate and adaptive immune responses. This investigation evaluates the anti-atopic dermatitis activity of a by-product from ethanol-extracted Chaga mushroom (E-CME), positioning it as a sustainable natural candidate for AD therapeutic development. The antioxidant potential of E-CME was assessed using DPPH radical scavenging, H2O2 scavenging, metal chelation, and FRAP assays. In vitro, its immunomodulatory effects were evaluated in HaCaT and RBL-2H3 cell lines by measuring cytokine release and β-Hexosaminidase activity. For in vivo analysis, E-CME was topically applied to BALB/c mice sensitized with Dermatophagoides farinae extract (DFE), with AD induced by DNCB. Post-treatment, inflammatory cytokine expression and MAPK marker expression were examined. E-CME treatment significantly improved dermatitis scores (p < 0.05), mast cell infiltration, serum immunoglobulin levels (24.07% increase of IgG2, 26.19% decrease of IgE), oxidative stress markers, and skin cytokine gene expression. Spleen and lymph node weights, plus splenocyte viability, also improved with E-CME treatment. These findings suggest that E-CME possesses substantial therapeutic potential for AD management, attributed to its antioxidant and immunomodulatory effects, possibly mediated by the inhibition of oxidative stress-associated inflammatory pathways.

## Linked entities

- **Chemicals:** DNCB (PubChem CID 6), H2O2 (PubChem CID 784)
- **Diseases:** atopic dermatitis (MONDO:0004980)
- **Species:** Dermatophagoides farinae (taxon 6954)

## Full-text entities

- **Genes:** Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Il21 (interleukin 21) [NCBI Gene 60505] {aka IL-21}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Oga (O-GlcNAcase) [NCBI Gene 154968] {aka Mgea5, Ncoat}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Oga (O-GlcNAcase) [NCBI Gene 76055] {aka Hy5, Mgea5, Ncoat}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Ighv1-9 (immunoglobulin heavy variable 1-9) [NCBI Gene 668478] {aka Gm16697, Igg2a}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Il5 (interleukin 5) [NCBI Gene 16191] {aka Il-5}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}
- **Diseases:** inflammatory skin diseases (MESH:D012871), allergic diseases (MESH:D004342), hypertrophy (MESH:D006984), anorexia (MESH:D000855), lymphadenopathy (MESH:D008206), dysfunction (MESH:D006331), itching (MESH:D011537), Inflammation (MESH:D007249), eczema (MESH:D004485), eczematous lesions (MESH:D017443), psoriasis (MESH:D011565), AD (MESH:D003876), hepatic and renal toxicity (MESH:D056486), weight loss (MESH:D015431), edema (MESH:D004487), histopathological abnormalities (MESH:D000014), growth retardation (MESH:D006130), fibrosis (MESH:D005355), tumor (MESH:D009369), SD (MESH:D012735), cytotoxicity (MESH:D064420), dryness (MESH:D014987), hemorrhage (MESH:D006470), skin atrophy (MESH:D001284), Dermatitis (MESH:D003872), erythema (MESH:D004890), epidermal hyperplasia (MESH:D006965), skin injuries (MESH:D000069836), splenomegaly (MESH:D013163), cutaneous irritation (MESH:D001523), cataracts (MESH:D002386), immune dysregulation (OMIM:614878), acne (MESH:D000152)
- **Chemicals:** Hematoxylin (MESH:D006416), CO2 (MESH:D002245), MTT (MESH:C070243), flavonoids (MESH:D005419), paraffin (MESH:D010232), PBS (MESH:D007854), H2O2 (MESH:D006861), water (MESH:D014867), polysaccharides (MESH:D011134), HEPES (MESH:D006531), MDA (MESH:D008315), gallic acid (MESH:D005707), free radicals (MESH:D005609), Dermatop (MESH:C035287), DMSO (MESH:D004121), ursolic acid (MESH:C005466), streptomycin (MESH:D013307), ethanol (MESH:D000431), EDTA (MESH:D004492), imiquimod (MESH:D000077271), acetone (MESH:D000096), sterols (MESH:D013261), A23187 (MESH:D000001), phosphate (MESH:D010710), acetate (MESH:D000085), penicillin (MESH:D010406), DNCB (MESH:D004137), phelligridin D (MESH:C000631946), BA (MESH:D000094062), TE (MESH:D013691), paraformaldehyde (MESH:C003043), H&amp;E (MESH:D006371), DPPH (MESH:C004931), eosin (MESH:D004801), ergosterols peroxide (MESH:C036071), E (MESH:D004540), terpenes (MESH:D013729), heavy metal (MESH:D019216), lanosterol (MESH:D007810), ferrozine (MESH:D005297), melanin (MESH:D008543), polyphenol (MESH:D059808), inotodiol (MESH:C517091), L-glutamine (MESH:D005973), 2H, E-CME (-), Formazan (MESH:D005562), isopropanol (MESH:D019840), lupeol (MESH:C010480), citrate (MESH:D019343), glycine (MESH:D005998), 2,4,6-tri(2-pyridyl)-s-triazine (MESH:C002849), Metal (MESH:D008670), Trolox (MESH:C010643), triterpenoids (MESH:D014315), 3,4-dihydroxybenzalacetone (MESH:C546059), glucans (MESH:D005936), formalin (MESH:D005557), nitrogen (MESH:D009584), ABTS (MESH:C002502), TRIzol (MESH:C411644)
- **Species:** Homo sapiens (human, species) [taxon 9606], Agaricus bisporus (common mushroom, species) [taxon 5341], Mus musculus (house mouse, species) [taxon 10090], Inonotus obliquus (chaga, species) [taxon 167356]
- **Cell lines:** NC/Nga — Homo sapiens (Human), Transformed cell line (CVCL_1874), RBL-2H3 — Rattus norvegicus (Rat), Rat leukemia, Cancer cell line (CVCL_0591), T Helper — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_3174), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), /c — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_9103), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12861731/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12861731/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12861731/full.md

---
Source: https://tomesphere.com/paper/PMC12861731